Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Solid Tumors

NCT07256756 is registered in ClinicalTrials.gov with Shanghai Juncell Therapeutics as lead sponsor.

NCT NCT07256756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07256756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai Juncell Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
January 30, 2026
Completion date
November 30, 2028
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, adult